University of Buffalo Clinical and Translational Science Institute

点击翻译按钮获取中文摘要

CTSA UL1 Abstract The Buffalo Translational Consortium (BTC), which includes the University at Buffalo (UB) health sciences schools, the major healthcare institutions in our region, four key research institutes and five influential community partners, have embarked on a comprehensive strategic plan to build a strong foundation for clinical and translational research in response to our community needs. Buffalo is the second most populous city in New York State and has a rich cultural history. The proportion of underrepresented minorities in Buffalo in 2018 (50%) parallels that projected for the US in 2050, making Buffalo a microcosm of what the US will look like in 30 years. A similar proportion of our population experiences health disparities. The vision for our CTSA hub is to perform innovative research across the translational spectrum to improve the health of our community and the nation. We will develop, test and share novel approaches to engage difficult-to-engage populations and reduce health disparities in our community, which represents a “population of the future”. Guided by our vision, the CTSA has catalyzed a transformation of our environment since our CTSA was first funded in August 2015 with remarkable growth in clinical and translational research. Further, in just the past year, the UB medical school has moved into a spectacular new building and our clinical partner, Kaleida Health, the largest healthcare system in the region, opened the new Oishei Children’s Hospital, both on the Buffalo Niagara Medical Campus and connected to the Clinical and Translational Research Center devoted entirely to clinical and translational research that opened in 2012. This rapid and continuing trajectory of growth in healthcare and research in the region has resulted in a new 21st century Academic Health Center with healthcare, medical education and clinical and translational research on one campus in the heart of Buffalo, creating a foundation to enhance the impact of our CTSA even further. While launching our CTSA, we have prioritized participation in the national consortium through hosting and testing Innovation Labs as a team science tool, working with multiple hubs on initiatives to solve translational research barriers and sharing tools that we have developed with the CTSA consortium, including novel health informatics tools. Our CTSA has five ambitious but achievable aims, including: 1) Accelerate innovative translational research with teams that engage communities, regional stakeholders and the national consortium; 2) Train an excellent, diverse workforce to advance translation of discoveries; 3) Enhance inclusion of special populations across the lifespan and difficult-to-engage populations; 4) Streamline clinical research processes focusing on quality and efficiency with emphasis on multisite studies; 5) Develop, test and share biomedical informatics tools to integrate data from multiple sources to speed translation. Guided by our vision to perform research to improve the health of our community and the nation, we will continue our momentum to expand translational research, train our diverse workforce, streamline processes, engage our community, and actively contribute to the national consortium. CTSA Diversity Supplement: Bacterial Derived Aortic Endothelial Dysfunction to Promote Atherosclerosis Dayron Leya Rodriquez, the candidate for this diversity supplement is of Hispanic background and completion of this supplement award will allow him to gain academic knowledge, research skills and professional development in the areas of clinical and translational research. This proposal encompasses aims of the parent CTSA UL1 award to 1) train an excellent diverse workforce to advance translational and health-related research with 2) ehnanced inclusion of special populations. To complete the proposed supplemental research, Dayron will utilize the following CTSA cores: • Biostatistics, Epidemiology and Research Design (BERD) Core: Dayron will leverage the expertise and support of his mentor Dr. Greg Wilding (Director of BERD), for appropriate statistical experimental design and analysis of all experimental data. He will also complete the BERD Statistical workshops and BERD Clinical Trials workshops series to gain competency in aspects applicable to clinical and translational research. • Workforce Development Core: Dayron will complete workshop series (each containing 4-8 individual workshops) in the areas of a) Responsible Conduct of Research, b) Scientific Communication, c) Translational Teamwork and d) Good Clinical Practice. Following completion of each series, Dayron will be awarded a Digital Badge and with completion of all these workshops will earn his CTSI Basic Micro-credential in Clinical and Translational Reseach. • Cinical Research Facilitation Core: Dayron and our research team will work with faciltators to continue successful recruitment strategies including flyers and advertising as well as access to patient databases such as the Buffalo Research Registry to recruit local volunteers. Consultation with the Community Engagement Core will facilitate appropriate community recruitment of subjects from both genders and diverse ethnic backgrounds to increase the robustness of our subject population and collected data. • Laboratory Facility Cores. Dayron will utilize the Confocal Microscope and Flow Cytometry Facility and Next Generation Seqeuncing and Expression Facility for completion of the proposed experiments.